Multicentric Oncologic Outcomes of High-Intensity Focused Ultrasound for Localized Prostate Cancer in 803 Patients
Multicentric Oncologic Outcomes of High-Intensity Focused Ultrasound for Localized Prostate Cancer in 803 Patients
复制标题
DOI：
10.1016/j.eururo.2010.06.037
复制
发表时间：
2010-10-01
期刊：
影响因子：
23.4
通讯作者：
Gelet, Albert
中科院分区：
文献类型：
--
作者：
Crouzet, Sebastien;Rebillard, Xavier;Gelet, Albert
背景：高强度聚焦超声(HIFU)是一种新兴的治疗局限性前列腺癌(PCA)的方法。目的：从多中心数据库中报道HIFU作为治疗局限性前列腺癌的主要治疗方案的肿瘤学结果。设计、设置和对象：这项研究考虑了有治疗意图且从1993年2月开始至少随访2年的局限性前列腺癌患者。以前接受过放射治疗的患者被排除在这项分析之外。对于任何残留或复发的PCA，系统地为患者提供第二次疗程。通过Kaplan-Meier分析确定无病生存率(DFSR)。测量指标：前列腺特异性抗原(PSA)、临床分期和病理结果在HIFU治疗前后进行测量。结果与限制：来自6个泌尿外科的803例患者符合纳入标准。根据d‘Amico’s危险组的分层，分别有40.2%、46.3%和13.5%的患者为低、中、高分层。平均随访时间为42+/-33个月。平均PSA最低值为1.0+/-2.8 ng/ml，其中54.3%达到最低点
Background: High-intensity focused ultrasound (HIFU) is an emerging treatment for select patients with localized prostate cancer (PCa).Objectives: To report the oncologic outcome of HIFU as a primary care option for localized prostate cancer from a multicenter database.Design, setting, and participants: Patients with localized PCa treated with curative intent and presenting at least a 2-yr follow-up from February 1993 were considered in this study. Previously irradiated patients were excluded from this analysis. In case of any residual or recurrent PCa, patients were systematically offered a second session. Kaplan-Meier analysis was performed to determine disease-free survival rates (DFSR).Measurements: Prostate-specific antigen (PSA), clinical stage, and pathologic results were measured pre- and post-HIFU.Results and limitations: A total of 803 patients from six urologic departments met the inclusion criteria. Stratification according to d'Amico's risk group was low, intermediate, and high in 40.2%, 46.3%, and 13.5% of patients, respectively. Mean follow-up was 42 +/- 33 mo. Mean PSA nadir was 1.0 +/- 2.8 ng/ml with 54.3% reaching a nadir of